Table 1.

Moderate hypofractionation trials.

Trial	Design	pts randomized	Patient population (NCCN)	Fractionation and Total dose	5-year FFF1 rate
CHHiP	Non-inferiority	3216	73% IR2	37 X 2Gy, 74GY 20 X 3Gy, 60Gy 19 X 3Gy, 57Gy	88.3% 90.6% 85.9%
PROFIT	Non-inferiority	1206	100% IR	39 X 2Gy, 78Gy 20 X 3Gy, 60Gy	79% 79%
RTOG 0415	Non-inferiority	1092	100% LR3	41 X 1.8Gy, 73.8Gy 28 X 2.5Gy, 70Gy	85.3% 86.3%
HYPRO	Superiority	804	73% HR4	39 X 2Gy, 78GY 19 X 3.4Gy, 64.6Gy	77% 81%
Pollack et al.	Superiority	303	64% HR	38 X 2Gy, 76Gy 26 X 2.7GY, 70.2Gy	85% 81%
Arcangeli et al.	Superiority	168	76% HR	40 X 2Gy, 80Gy 20 X 3.1Gy, 62Gy	79% 85%
Hoffman et al	Superiority	204	70% IR	42 X 1.8Gy, 75.6GY 30 X 2.4Gy, 72Gy	92% 96%

¹FFF: freedom from failure.

²IR: intermediate risk.

³LR: low risk.

⁴HR: high risk.